Ceapro Announces Grant of Stock Options
Ceapro announced the granting of stock options to employees, officers, and directors totaling 740,000 common shares at an exercise price of $0.62.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ceapro announced the granting of stock options to employees, officers, and directors totaling 740,000 common shares at an exercise price of $0.62. The options will vest in three equal installments over two years, with the first installment vesting immediately. Each option is exercisable for five years from the grant date and is subject to TSX Venture approval. This move aims to incentivize key personnel and aligns their interests with company performance.
Positive
- Issuance of 740,000 stock options to employees and directors, promoting retention and performance alignment.
- Options granted at an exercise price of $0.62, which may represent a favorable potential for future appreciation.
Negative
- None.
Details
News Market Reaction – CRPOF
The recorded move for CRPOF in the trading session of this news was -0.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) to employees, officers and directors of the Company.
Options to purchase 740,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an exercise price of
The granting of all options is subject to TSX Venture approval.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.
For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@itcir.com
Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.